Compare ARK Genomic Revolution ETF (ARKG) vs Home Depot Inc (HD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Home Depot Inc — how do they compare? ARK Genomic Revolution ETF trades at $44.53, while Home Depot Inc trades at $354 (market cap $353.46B). The key difference: Home Depot Inc pays a 2.63% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Home Depot Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | HD | |
|---|---|---|
Sector | Sector/Thematic | Consumer Cyclical |
52-Week High | $44.55 | $423.42 |
52-Week Low | $24.02 | $297.51 |
Market Cap | — | $353.46B |
Enterprise Value | — | $415.01B |
Dividend Yield | — | 2.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG, the ARK Genomic Revolution ETF, trades at $43.04, up 6.06% in the past 24 hours, with a bullish technical signal from moving averages and ADX indicators. The ETF focuses on small- and mid-cap biotech stocks, with its top 10 holdings comprising 59% of the portfolio and a long-term EPS growth rate of 10.7%. Recent news highlights its recovery from a 15% correction, with support emerging at key levels.
The outlook for ARKG is positive, driven by biotech sector tailwinds including a friendlier FDA, strong M&A activity, and AI-driven drug discovery. Risks include high concentration in volatile biotech names and sensitivity to broader market sell-offs. Investors should weigh the growth potential against the inherent volatility of genomics investments.
Home Depot (HD) trades at $350.78, down 1.36% on the day, with a bullish technical outlook supported by moving averages and strong institutional support. The company reported $159.51B in revenue for 2025 with solid profitability metrics including 8.41% net margin and 128.38% ROE. Recent earnings show mixed results with Q2 2026 expectations at $4.73 EPS. Analyst consensus remains positive with 59% buy ratings and a $371.25 price target, representing 5.8% upside potential.
The stock presents a compelling long-term opportunity given strong fundamentals and analyst optimism, though near-term headwinds include weakening big-ticket demand and margin pressure from investments. Housing market sensitivity and competitive pressures remain key risks, but Pro business growth and digital initiatives provide resilience. Current valuation at 24.91 P/E appears reasonable for the quality franchise.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Home Depot Inc
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). The addition of the Company Store brought textile exposure to Home Depot's lineup.
Read more on HD →
